Proposed FDA nanotech programme would develop best practices for industry
This article was originally published in Clinica
Executive Summary
The FDA’s National Center for Toxicological Research (NCTR) would be the “ideal candidate” for studying the safety of nanotech materials used in medical devices, drugs and biologics, Senator Mark Pryor said on introducing legislation into Congress on nanotech safety.
You may also be interested in...
US: The sun shines in on industry-doctor relationships
The US healthcare reform proposals signed into law on 23 March include requirements on medical device companies to reveal payments or gifts they make to doctors. Peter Rixon takes a closer look at what the reforms’ “sunshine” provisions actually mean
Global regulators/industry to gather in US and Germany to talk device regulation
Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in the coming weeks.
Global regulators and industry execs to gather in US and Germany to talk device regulation
Compliance, approvals, inspections and many other burning issues will be on the agenda of a US conference that takes place in early May.